Inhibition of breast cancer cell proliferation and unique epitope recognition by EpCAM-specific human monoclonal antibody adecatumumab
Muenz, M. et. al. Annual Meeting of AACR Abstract No. 5339 (2010)

Overexpression of EpCAM in uterine serous papillary carcinoma: Implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201)
El-Sahwi, K. et. al. Mol Cancer Ther 9: 57–66 (2010)

The emerging role of EpCAM in cancer and stem cell signaling
Muenz, M., Baeuerle, P. A., Gires, O. Cancer Res 69: 5627-5629 (2009)

Potential therapeutic activity of adecatumumab (MT201), a fully human monoclonal antibody, against epithelial cell adhesion molecule (EpCAM) in uterine serous papillary carcinoma
Santin, A. et. al. J Clin Oncol 27: Abstract No. e16502 (2009)

EpCAM’s renaissance
Baeuerle, P.A. and Ruettinger, D. Drug Discovery & Development, www.dddmag.com, April 9 (2009) 

Nuclear signalling by tumour-associated antigen EpCAM
Maetzel, D. et. al. Nat Cell Biol 11: 162-171 (2009)

Rationale for treatment of colorectal cancer with EpCAM targeting therapeutics
Baeuerle, P.A., Riethmueller, G. In: Tumor-associated antigens: identification, characterization and clinical application (Gires, O., Seliger, B., eds.)  Wiley-VHC, Weinheim, pp. 179-200 (2009)

On the abundance of EpCAM on cancer stem cells
Gires, O. et. al. Nature Reviews Cancer Jan. 9, epub ahead of print (2009)

First results from a phase Ib study of the anti-EpCAM antibody
adecatumumab (MT201) in combination with docetaxel in
patients with metastatic breast cancer
Schuler, M. et. al. Annual Meeting of ESMO, Abstract No. 485p (2008)

Nuclear signalling by tumour- and stem cell-associated antigen EpCAM (CD326)
Gires, O. et al. Annual Meeting of AACR-NCI-EORTC Abstract No. C175 (2007)

Apparent lack of immunogenicity of human antibody adecatumumab in breast and prostate cancer patients
Wolf, A. et al. Annual Meeting of AACR-NCI-EORTC Abstract No. B49 (2007)

Highly reduced incidence of new breast cancer metastases during treatment with adecatumumab appears to be the major factor for longer time to tumor progression in patients with high-level EpCAM expression
Dittrich, C. et al. Annual Meeting of AACR-NCI-EORTC Abstract No. A71 (2007)

EpCAM (CD326) – finding its role in cancer     
Baeuerle, P.A. and Gires, O. Brit J Cancer 96: 417-423 (2007)

Exchanging human lg gamma 1 with murine lg gamma 2a highly potentiates anti-tumor activity of anti-EpCAM antibody adecatumumab in a syngeneic mouse lung cancer model
Lutterbuese, P. et al. Cancer Immunol Immunother 56: 459-468 (2007)

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer     
Spizzo, G. et al. Gynecol Oncol 103: 483-488 (2006)

A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients
Oberneder, R.  et al.  Eur J Cancer 42: 2530-2538 (2006)

Frequent high-level expression of immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung carcinomas
Went, P. et al. Brit J Cancer 94 :128-135 (2006)

High concentrations of therapeutic antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess immunoglobulin G
Preithner, S. et al. Mol Immunol 43: 1183-1193 (2006)

Cellular and complement-dependent cytotoxicity of monoclonal antibody MT201 against human breast cancer cell lines
Prang, N. et. al. Brit J Cancer 92: 342-349 (2005)

Cytotoxic activity of novel monoclonal antibody MT201 against primary ovarian tumor cells
Xiang, W. et al. J Canc Res Clin Oncol 129: 341-348 (2003)

In-vitro and in-vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment
Naundorf, S. et al. Int J Cancer 100: 101-110 (2002)